Physiological, hematological and biochemical factors associated with high-altitude headache in young Chinese males following acute exposure at 3700 m

Kun Wang1,3, Menghan Zhang2,3, Yi Li2,3,6, Weilin Pu2, Yanyun Ma2,3,6, Yi Wang2,3, Xiaoyu Liu2,3, Longli Kang5, Xiaofeng Wang1,3, Jiucun Wang1,3,6, Bin Qiao4 and Li Jin1,3,6*

Abstract

Background: High-altitude headache (HAH) is the most common sickness occurred in healthy people after rapid ascending to high altitude, and its risk factors were still not well understood. To investigate physiological, hematological and biochemical risk factors associated with high-altitude headache (HAH) after acute exposure to 3700 m, we conducted a two-stage, perspective observational study. In 72 h, total 318 young Han Chinese males ascended from sea level (altitude of 50 m) to altitude of 3700 m by train. Demographic data, physiological, hematological and biochemical parameters of all participants were collected within one week prior to the departure, and within 24 h after arrival.

Results: The incidence of HAH was 74.84%. For parameters measured at sea level, participants with HAH exhibited significantly higher age and lower BUN (p < 0.05). For parameters measured at 3700 m, participants with HAH exhibited significantly lower blood oxygen saturation (SpO2), higher resting heart rate (HR), higher systolic blood pressure at resting (SBP) and lower blood urea nitrogen (BUN) (all p < 0.05). At 3700 m, the severity of HAH associated with SpO2, HR and BUN significantly (all p < 0.05). Multivariate logistic regression revealed that for parameters at sea level, BUN was associated with HAH [BUN (OR:0.77, 95% CI:0.60–0.99)] and for parameters at 3700 m, SpO2, HR and BUN were associated with HAH independently [SpO2 (OR:0.84, 95% CI:0.76–0.93); HR (OR:1.03, 95% CI:1.00–1.07); BUN (OR:0.64, 95% CI:0.46–0.88)]. No association between hematological parameters and HAH was observed.

Conclusion: We confirmed that higher HR, lower SpO2 are independent risk factors for HAH. Furthermore, we found that at both 50 m and 3700 m, lower BUN is a novel independent risk factor for HAH, providing new insights for understanding the pathological mechanisms.

Keywords: High-altitude headache, Hypoxia, Blood urea nitrogen, Oxygen saturation, Heart rate
Background
For lowlanders who rapidly ascend to altitude above 2500 m, headache has been considered as the most frequent complaint [1, 2]. According to the most widely-accepted diagnose criteria, the Lake Louise Consensus scoring system identified headache as the cardinal symptom of acute mountain sickness (AMS) [3]. The International Headache Society defined high altitude headache (HAH) as a headache that develops within 24 h of ascent to high altitude and resolves within 8 h of descent [4, 5]. Previous studies have reported that the incidence of HAH is over 70% within 24 h after rapidly ascending above 2500 m [2].

Numerous studies have been emerged on epidemiology, clinical characteristics, pathophysiological mechanisms, treatment and risk factors of HAH [1, 6–8]. Recent studies suggested that the cause of HAH may be hypoxia-induced cerebral cytotoxic oedema, brain swelling and increased intracranial pressure [6]. In addition to oxygen inhalation, aspirin and acetaminophen were often used for HAH treatment, and the effect are contradictory [9, 10]. Several studies have demonstrated that young age, smoking history, higher body mass index history of migraine, high heart rate (HR) and low pulse oxygen saturation (SpO₂) are independent risk factors for HAH [1, 11–13]. Previously, Huang et al. performed the first investigation on the relationship between hematological parameters and HAH before and after rapid ascending to 3700 m with 45 subjects, and found that HAH is associated with sea-level reticulocyte and neutrophil counts [14]. Because erythrocytes are the principal carrier of oxygen in the circulatory system, the hematological parameters may provide useful information regarding HAH. Moreover, some studies demonstrated that fluid retention is an important feature of AMS, but other studies have demonstrated that low fluid intake is an independent risk factor of HAH, and glomerular filtration rate estimates increases with AMS severities after rapid ascent to high altitude [15–18]. Over all, most of the studies had small sample sizes, the results were contradictory, and no definitive clear answer is available.

The present study was based on the hypothesis that some hematological and biochemical parameters would be related with HAH. We aimed to explore the association between physiological, hematological, biochemical parameters (including renal function parameters) and the risk of HAH after a 3-days ascending to the altitude of 3700 m. We carried out a repeated measurement design based on two phases (50 m and 3700 m) before and after ascending at high altitude for 318 healthy young Han Chinese males. Physical, hematological and biochemical parameters were collected at each phase, respectively.

Methods
Participants
In total, 318 young Chinese males who lived at 50 m and ascended to Tibet for physical training were recruited in this study. All participants reported their disease history, medication history, smoking and drinking history in structured case report forms (CRFs). The inclusion criteria were healthy 18–35 year old Han Chinese men whose primary residence was at an altitude of ≤1000 m and had no high-altitude exposure in recent 2 years. The exclusion criteria were cardio-cerebrovascular diseases, neurological and psychiatric diseases, episodic or chronic migraine diseases or chronic headache symptoms (any headache occurring on more than 2 weeks/month), autoimmune diseases, respiratory diseases, malignancy, liver and kidney dysfunction, active infection or a bad cold. Participants who took acetazolamide, diuretics, steroids or nonsteroidal anti-inflammatory drugs during the ascending were excluded. Subjects who agreed to participate underwent a short instruction and explanation of the purpose of this study, and all participants have signed the informed consent before their first examinations. The study was approved by the Human Ethics Committee of Fudan University.

Study procedures and measurements
All participants ascended to altitude of 3700 m (Lhasa, Tibet) within 72 h by train from sea level (altitude of 50 m, Henan). The baseline physiological, hematological and biochemical measurements were performed in the morning, one week prior to the departure at 50 m. Within 24 h after their arrival at 3700 m, the participants underwent assessments of their physiological, hematological and biochemical parameters, as well as HAH. All participants were monitored by trained physicians for any signs of high-altitude cerebral or pulmonary edema, and immediate treatment will be addressed for emergent cases [19]. During the period of study, all participants maintained the same diet. Caffeine beverage consumption, alcohol consumption and medication use were prohibited, smoking and heavy exercises or physical labor were also avoided.

Structured case report forms (CRFs) were used to record the demographic data (age, body mass index (BMI), chest circumstance, smoking and drinking history) and all measurements at sea level and 3700 m for each participants. After the acute exposure at 3700 m, the physicians scored HAH based on self-description of patients (0 = no headache; 1 = mild headache; 2 = moderate headache; 3 = severe headache) was recorded, and the time and place of headache onset was recorded retrospectively. We used a two-repeated measurement method to collect the heart rate at resting (HR, beats/min), systolic blood pressures at resting (SBP, mmHg), diastolic blood
pressure at resting (DBP, mmHg) and Oxygen saturation (SpO₂, %), operated twice by two independent professional physicians and recorded the average value. SBP and DBP were measured using a standardized mercury sphygmomanometer, while SpO₂ was measured using Nellcor NPB-40 (USA).

Morning fasting venous blood (4 ml) was collected with EDTA-K2 at both sea level and 3700 m, and 2 ml of the samples were used to assay blood cell parameters by a hematology analyzer (Sysmex pocH-100i, Japan) within 2 h. The hematological parameters included red blood cell count (RBC, × 10¹²/L), hemoglobin (Hgb, g/L), hematocrit (Hct, %), mean corpuscular volume (MCV, fl), mean corpuscular hemoglobin (MCH, pg), white blood cell count (WBC, × 10⁹/L), lymphocyte percentage (LYM%), absolute lymphocyte count (LYM#), platelet count (PLT, × 10⁹/L) and mean platelet volume (MPV, fl). The rest 2 ml blood specimens were centrifuged 3000 r/min for 10 minus to separate plasma. Biochemical parameters including alanine aminotransferase (ALT, U/L), aspartate aminotransferase (AST, U/L), blood urea nitrogen (BUN, mmol/L), serum creatinine (CREA, umol/L), total serum bilirubin (T-BIL, umol/L), direct serum bilirubin (D-BIL, umol/L) and indirect serum bilirubin (I-BIL, umol/L) were measured using automatic biochemistry analyzer (TOSHIBA TBA-120FR).

The diagnosis of HAH was based on the International Classification of Headache Disorders 3β criteria [5], but not strictly (no test for descending), restricted by the complex situations of field study.

**Statistical analyses**

The normality of continuous data was assessed by Shapiro-Wilk’s test. Normally distributed data were presented as the means±standard deviations (SD), non-normally distributed data were presented as median (interquartile range, IQR) and enumerated data were expressed as numbers (%). The differences of measurements between sea level and 3700 m were compared using paired-sample student’s t-test for normally distributed data, and the comparisons of differences between HAH positive (HAH+) and HAH negative (HAH-) groups were analyzed by independent student’s t-test. The non-normally data were compared using the Mann-Whitney U test. The spearman correlations between HAH score and the measurements at sea level and 3700 m were analyzed. Univariate logistic
regression was performed to assess the relationships between each measurement and HAH at 3700 m. Significant variables in any of the above three analyses were included in forward stepwise multivariable logistic regression, and analyzed separately at sea level and 3700 m. The significant level of $p$-value is 0.05 (two-tailed). The analyses flowchart was shown in Fig. 1.

**Results**

Total 318 participants had complete CRFs, physiological, hematological and biochemical measurements (Additional file 1). The mean age and BMI of the participants in this study were 21.87 ± 3.33 years and 22.06 ± 1.99 kg/m². The incidence of HAH after acute exposure to 3700 m is 74.84% (Additional files 2 and 3).

**Alterations in physiological, hematological and biochemical measurements**

Most of the physiological, hematological and biochemical parameters were dramatically altered after acute exposure to high altitude from sea level, beside of Hct, MCH and LYM%. For the physiological measurements, SpO₂

### Table 1 Comparison of physiological, hematological and biochemical parameters between sea level and 3700 m ($N = 318$)

| Measures at sea-level                      | Measurements at 3700 m                      | $p$   |
|-------------------------------------------|--------------------------------------------|-------|
| Demographic data                          |                                            |       |
| Age, y                                     | 21.87 ± 3.33                               | the same as sea-level                      | –     |
| BMI, kg/m²                                 | 22.06 ± 1.99                               | the same as sea-level                      | –     |
| chest circumstance, cm                     | 86.11 ± 5.09                               | the same as sea-level                      | –     |
| Smoking, yes(%)                            | 102 (32.1)                                 | the same as sea-level                      | –     |
| Drinking, yes(%)                           | 39 (12.3)                                  | the same as sea-level                      | –     |
| Physical parameters                        |                                            |       |
| SpO₂, %                                    | 98.00 (98.00–98.20)                        | 88.00 (85.10–90.20)                       | < 0.001** |
| HR, beats/min                              | 67.49 ± 9.18                               | 84.17 ± 12.15                             | < 0.001** |
| SBP, mmHg                                  | 111.22 ± 9.81                              | 120.52 ± 12.8                             | < 0.001** |
| DBP, mmHg                                  | 71.85 ± 8.14                               | 81.77 ± 9.56                              | < 0.001** |
| Hematological parameters                   |                                            |       |
| RBC, *10¹²                                 | 5.00 (4.80–5.20)                           | 5.11 (4.82–5.49)                          | < 0.001** |
| Hgb, g/L                                   | 151.10 (144.00–157.00)                     | 157.00 (147.00–169.30)                    | < 0.001** |
| Hct, %                                     | 44.49 ± 3.10                               | 48.42 ± 6.08                              | < 0.001** |
| MCV, fl                                    | 92.20 (90.00–94.22)                        | 86.50 (84.40–88.62)                       | < 0.001** |
| MCH, pg                                    | 30.59 (29.61–31.30)                        | 30.90 (30.20–32.10)                       | < 0.001** |
| PLT, *10⁹                                 | 206.79 ± 44.77                             | 244.97 ± 69.80                            | < 0.001** |
| MPV, fl                                    | 10.50 (9.80–11.00)                         | 10.60 (10.20–11.00)                       | 0.006** |
| WBC, *10³                                 | 6.10 (5.40–7.10)                           | 7.90 (7.00–9.50)                          | < 0.001** |
| LYM%, %                                    | 36.23 ± 7.59                               | 36.49 ± 9.06                              | 0.833  |
| LYM#, *10⁹                                | 2.20 (1.90–2.60)                           | 2.95 (2.50–3.40)                          | < 0.001** |
| Biochemical parameters                     |                                            |       |
| ALT, U/L                                   | 18.00 (15.00–23.00)                        | 39.20 (30.40–48.50)                       | < 0.001** |
| AST, U/L                                   | 15.10 (12.30–18.50)                        | 31.00 (25.50–40.60)                       | < 0.001** |
| BUN, mmol/L                                | 4.45 (3.89–5.28)                           | 4.60 (4.10–5.25)                          | 0.109  |
| CREA, umol/L                               | 58.00 (49.00–68.10)                        | 105.40 (98.60–114.00)                     | < 0.001** |
| TBIL, umol/L                               | 12.60 (10.80–14.00)                        | 12.30 (10.20–15.65)                       | 0.023* |
| DBIL, umol/L                               | 3.10 (2.30–3.50)                           | 4.70 (3.90–5.80)                          | < 0.001** |
| IBIL, umol/L                               | 9.70 (8.50–10.50)                          | 7.70 (5.80–10.65)                         | < 0.001** |

$\text{SpO}_2$: blood oxygen saturation,
$\text{HR}$: heart rate at resting,
$\text{SBP}$: systolic blood pressure,
$\text{DBP}$: diastolic blood pressure,
$\text{RBC}$: red blood cell count,
$\text{Hgb}$: hemoglobin,
$\text{Hct}$: hematocrit,
$\text{MCV}$: mean corpuscular volume,
$\text{MCH}$: mean corpuscular hemoglobin,
$\text{PLT}$: platelet count,
$\text{MPV}$: mean platelet volume,
$\text{WBC}$: white blood cell,
$\text{LYM}$: lymphocyte rate,
$\text{LYM}$#: lymphocyte count,
$\text{ALT}$: alanine aminotransferase,
$\text{AST}$: aspartate aminotransferase,
$\text{BUN}$: blood urea nitrogen,
$\text{CREA}$: creatinine,
$\text{TBIL}$: total serum bilirubin,
$\text{DBIL}$: direct serum bilirubin,
$\text{IBIL}$: indirect serum bilirubin

Normally distributed variables were presented as mean ± SD, and compared using paired-sample T test; Non-normally distributed variables were presented as mean (interquartile range), and compared using Mann-Whitney U test.

*p value indicates $p < 0.05$; **p value indicates $p < 0.01$
Table 2

|                               | Measurement at sea level |       | Measurement at 3700 m |       |
|-------------------------------|--------------------------|-------|-----------------------|-------|
|                               | HAH+ (n = 238)           | HAH- (n = 80) | p                | HAH+ (n = 238) | HAH- (n = 80) | p                |
| **Demographic data**          |                          |        |                      |        |
| Age (year)                    | 22.05 ± 3.53             | 21.30 ± 2.69 | 0.046*              | The same as sea-levels |
| BMI (kg/m²)                   | 22.08 ± 2.02             | 21.96 ± 1.86 | 0.662               | The same as sea-levels |
| Chest Circumference (cm)      | 86.19 ± 5.30             | 86.04 ± 4.59 | 0.813               | The same as sea-levels |
| Drinking (yes, %)             | 29 (12.2)                | 10 (12.5)  | 0.978               | The same as sea-levels |
| **Physiological parameters**  |                          |        |                      |        |
| SpO₂ (%)                      | 98.00 (97.90–98.00)      | 98.00 (98.00–98.00) | 0.171               | 88.00 (84.90–90.40) | 90.00 (87.30–92.10) | <0.001** |
| HR (beats/min)                | 67.72 ± 8.99             | 66.91 ± 9.86 | 0.522               | 85.30 ± 12.09 | 80.77 ± 11.75 | <0.001** |
| **Hematological parameters**  |                          |        |                      |        |
| RBC (×10¹²)                   | 5.00 (4.80–5.20)         | 5.00 (4.70–5.20) | 0.559               | 5.10 (4.83–5.48) | 5.11 (4.75–5.55) | 0.955 |
| Hgb (g/L)                     | 151.30 (144.00–157.00)   | 150.00 (143.80–158.10) | 0.945               | 157.00 (149.60–168.30) | 157.00 (144.50–170.40) | 0.641 |
| Hct (%)                       | 45.69 ± 2.46             | 45.70 ± 2.49 | 0.981               | 48.61 ± 5.95 | 47.83 ± 6.47 | 0.364 |
| MCV (fL)                      | 92.30 (90.00–94.75)      | 92.00 (90.20–94.10) | 0.598               | 86.50 (84.40–88.92) | 86.40 (84.30–87.75) | 0.336 |
| MCH (pg)                      | 30.60 (29.59–31.36)      | 30.59 (29.73–31.02) | 0.459               | 30.90 (29.95–32.10) | 31.00 (30.18–31.75) | 0.939 |
| PLT (×10³)                    | 207.95 ± 44.97           | 203.33 ± 44.27 | 0.438               | 244.8 ± 68.6 | 245.3 ± 73.8 | 0.960 |
| MPV (fL)                      | 10.50 (9.80–11.02)       | 10.40 (9.70–10.91) | 0.326               | 10.60 (10.20–11.03) | 10.60 (10.30–11.00) | 0.965 |
| WBC (×10³)                    | 6.00 (5.40–7.00)         | 6.50 (5.50–7.35) | 0.090               | 7.90 (7.10–9.50) | 7.95 (6.98–9.38) | 0.791 |
| LYM rate (%)                  | 36.60 ± 7.58             | 35.12 ± 7.56 | 0.144               | 36.53 ± 9.68 | 36.36 ± 6.89 | 0.871 |
| LYM count (×10⁹)              | 2.20 (1.90–2.60)         | 2.15 (1.90–2.60) | 0.703               | 3.00 (2.51–3.40) | 2.95 (2.58–3.50) | 0.910 |
| **Biochemical parameters**    |                          |        |                      |        |
| ALT (U/L)                     | 18.10 (15.00–24.10)      | 18.00 (14.00–21.00) | 0.187               | 39.20 (28.50–49.30) | 39.00 (29.30–46.80) | 0.563 |
| AST (U/L)                     | 15.20 (12.00–20.00)      | 14.00 (12.10–17.75) | 0.237               | 31.00 (25.00–40.25) | 32.00 (27.20–38.50) | 0.581 |
| BUN (mmol/L)                  | 4.38 (3.82–5.08)         | 4.69 (3.99–5.53) | 0.029*              | 4.50 (4.02–5.20) | 4.80 (4.40–5.40) | 0.003**  |
| CREA (umol/L)                 | 58.00 (49.00–65.00)      | 59.00 (50.10–68.20) | 0.082               | 105.30 (98.50–115.00) | 106.80 (99.70–113.30) | 0.811 |
| TBIL (umol/L)                 | 12.50 (10.80–14.00)      | 12.70 (10.85–14.00) | 0.876               | 12.75 (10.20–15.75) | 12.90 (10.20–15.50) | 0.709 |
| DBIL (umol/L)                 | 3.10 (2.30–3.50)         | 3.10 (2.15–3.50) | 0.553               | 4.85 (3.90–5.90) | 4.60 (3.80–5.80) | 0.274  |
| IBIL (umol/L)                 | 9.60 (8.50–10.43)        | 9.90 (8.50–10.55) | 0.933               | 7.60 (5.80–10.70) | 7.80 (6.00–10.40) | 0.877  |

**Note:** HAH high altitude headache, HAH+ with high-altitude headache, HAH- without high-altitude headache, SpO₂ blood oxygen saturation, HR heart rate at resting, SBP systolic blood pressure, DBP diastolic blood pressure, RBC red blood cell count, Hgb hemoglobin, Hct hematocrit, MCV mean corpuscular volume, MCHC mean corpuscular hemoglobin, PLT platelets count, MPV mean platelet volume, WBC white blood cell, LYM% lymphocyte rate, LYM% lymphocyte count, ALT alanine aminotransferase, AST aspartate aminotransferase, BUN blood urea nitrogen, CREA creatinine, TBIL total serum bilirubin, DBIL direct serum bilirubin, IBIL indirect serum bilirubin.

Normally distributed variables were presented as mean ± SD, and compared using student's t-test; Non-normally distributed variables were presented as mean (interquartile range), and compared using Mann-Whitney U test; Categorical variables were compared using fisher's exact test; *p value indicates p < 0.05; **p value indicates p < 0.01
(HAH+: 22.05 ± 3.53 vs HAH-: 21.30 ± 2.69, \( p = 0.046 \)) and significant lower BUN (HAH+: 4.35 (3.82–5.08) vs HAH-: 4.69 (3.99–5.53), \( p = 0.029 \)). There were no significant differences in the physiological and hematological measurements at sea level (all \( p > 0.05 \), Table 2).

Regarding the measurements at 3700 m, compared with the HAH- group, the HAH+ group had significant lower SpO2 (HAH+ 88.00 (84.90–90.40) vs HAH- 90.00 (87.30–92.10), \( p < 0.001 \)), lower SBP (HAH+ 119.74 ± 13.10 vs HAH- 123.41 ± 11.10, \( p = 0.046 \)) and lower BUN (HAH+: 4.50 (4.02–5.20) vs HAH- 4.80 (4.38–5.53), \( p = 0.003 \)). The HAH+ group also had significant higher HR than HAH- group (HAH+ 85.30 ± 12.09 vs HAH- 80.77 ± 11.75, \( p < 0.001 \)). The hematological measurements showed no significant differences between HAH+ and HAH- groups at 3700 m (all \( p > 0.05 \), Table 2).

### Relationship between physiological, hematological and biochemical parameters and HAH

We further used Spearman’s correlation analyses to explore the relationship between measurements and the HAH severity. For the measurements at sea level, no significant association was observed between demographic data or all measurements and HAH severity. For the measurements at 3700 m, HAH severity was significantly associated with SpO2 (\( r = 0.365, p < 0.001 \)), HR (\( r = 0.249, p = 0.002 \)) and BUN (\( r = -0.176, p = 0.006 \)). The hematological measurements showed no significant correlation with HAH severity (all \( p > 0.05 \), Table 3).

### Risk factors for HAH at sea level and 3700 m

To discover risk factors for HAH, we performed univariate logistic regression for all parameters at sea level and at 3700 m. Among the sea level parameters, the univariate logistic regression revealed that only BUN associated with HAH significantly (OR:0.78, 95% CI:0.61–0.99, \( p = 0.044 \)). Meanwhile, among the parameters at 3700 m, SpO2 (OR:0.85, 95% CI:0.77–0.90, \( p < 0.001 \)), HR (OR:1.03, 95% CI:1.01–1.06, \( p = 0.004 \)) and BUN (OR:0.72, 95% CI:0.55–0.93, \( p = 0.012 \)) exhibited significant association with HAH (Table 4).

Multivariate logistic regression was performed for parameters which showed significant associations with HAH in univariate logistic regression, correlated with headache score, or showed significant difference between HAH+ and HAH- groups. For parameters at sea level, only BUN showed significant protective effect on HAH (OR:0.77, 95% CI:0.60–0.99, \( p = 0.040 \)), but for parameters at 3700 m, multivariate logistic regression revealed that SpO2 (OR:0.84, 95% CI:0.76–0.93, \( p < 0.001 \)), HR (OR:1.03, 95% CI:1.00–1.07, \( p = 0.042 \)) and BUN (OR:0.64, 95% CI:0.46–0.88, \( p = 0.007 \)) were all independent risk factors for HAH (Table 5).

### Discussion

### Alterations in physiological, hematological and biochemical parameters

Our study identified alterations in physiological, hematological and biochemical parameters from sea level to altitude of 3700 m. High altitude hypoxia lead a reduction of SpO2, which may result in a decrease in...
the delivery of oxygen and energy to organs and tissues. Dropped blood oxygen level may stimulate carotid chemoreceptors and activate the autonomic nervous system, which results in the cardiac output improvement, finally leading to increased HR [20]. The observation of our study is in consistency with previous studies [1, 7, 13].

The low humidity, hypoxic tachypnea and reduced fluid intake can lead to insensible fluid lose at high altitude [15, 16]. In addition, within hours of exposure to high altitude hypoxia, hypoxic tachypnea may lead to respiratory alkalosis, increased natriuresis and diuresis, promoting fluid shift away from intravascular space, result in blood concentration, even hypovolemia [21]. Our study observed most hematological parameters (RBC, Hgb, Hct, MCH, MPV, WBC, LYM%, LYM#, ALT, AST, BUN, CREA, TBIL, DBIL, IBIL) were elevated from sea-level to altitude of 3700 m within a 72 h ascending processes, which also in consistency with previous studies [14].

Our study also observed that serum creatinine increased dramatically after ascent from sea level to 3700 m, indicating a significantly decreased estimated glomerular filtration

| Table 4 Univariate logistic regression for each measurements at sea level and 3700 m (N = 318) |
|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|
|                                  | Measurements at sea level         | β-coefficient | OR | 95% CI   | p         | Measurements at 3700 m |
|----------------------------------|----------------------------------|--------------|----|----------|-----------|-----------------------|
| Demographic Data                 |                                  |              |    |          |           |                       |
| age (y)                          |                                  | 0.076        | 1.08 | 0.99–1.19 | 0.090     | The same as sea level |
| BMI (kg/m2)                      |                                  | 0.028        | 1.03 | 0.90–1.18 | 0.674     | The same as sea level |
| Chest (cm)                       |                                  | 0.006        | 1.01 | 0.96–1.06 | 0.825     | The same as sea level |
| smoking                          |                                  | −0.249       | 0.76 | 0.42–1.33 | 0.453     | The same as sea level |
| drinking                         |                                  | −0.055       | 0.97 | 0.45–2.16 | 0.917     | The same as sea level |
| Physical parameters              |                                  |              |    |          |           |                       |
| SpO2 (%)                         |                                  | −0.058       | 0.94 | 0.75–1.12 | 0.555     | −0.176 | 0.84 | 0.77–0.90 | < 0.001** |
| HR (beats/min)                   |                                  | 0.010        | 1.01 | 0.98–1.04 | 0.501     | 0.032  | 1.03 | 1.01–1.06 | 0.004**  |
| SBP (mmHg)                       |                                  | −0.010       | 0.99 | 0.96–1.02 | 0.433     | −0.022 | 0.98 | 0.95–1.00 | 0.068     |
| DBP (mmHg)                       |                                  | −0.009       | 0.99 | 0.96–1.02 | 0.576     | −0.017 | 0.98 | 0.95–1.01 | 0.291     |
| Hematological parameters         |                                  |              |    |          |           |                       |
| RBC (*10¹²)                      |                                  | −0.197       | 0.82 | 0.39–1.76 | 0.605     | 0.072  | 1.07 | 0.75–1.55 | 0.696     |
| HGB (g/L)                        |                                  | −0.002       | 1.00 | 0.97–1.03 | 0.906     | 0.004  | 1.00 | 0.99–1.02 | 0.460     |
| HCT (%)                          |                                  | −0.001       | 1.00 | 0.90–1.11 | 0.981     | 0.022  | 1.02 | 0.98–1.07 | 0.341     |
| MCV (fL)                         |                                  | 0.014        | 1.01 | 0.96–1.06 | 0.580     | 0.020  | 1.02 | 0.98–1.07 | 0.356     |
| MCH (pg)                         |                                  | 0.023        | 1.02 | 0.89–1.16 | 0.718     | 0.015  | 1.02 | 0.92–1.13 | 0.770     |
| PLT (*10⁹)                       |                                  | 0.002        | 1.00 | 0.99–1.01 | 0.439     | 0.000  | 1.00 | 0.99–1.01 | 0.959     |
| MPV (fL)                         |                                  | 0.136        | 1.15 | 0.88–1.51 | 0.320     | 0.039  | 1.04 | 0.70–1.56 | 0.847     |
| WBC (*10⁹)                       |                                  | −0.153       | 0.86 | 0.71–0.93 | 0.105     | 0.041  | 1.04 | 0.92–1.19 | 0.525     |
| LYM% (%)                         |                                  | 0.013        | 1.01 | 0.99–1.06 | 0.959     | 0.002  | 1.00 | 0.97–1.03 | 0.890     |
| LYM# (*10⁹)                      |                                  | 0.026        | 1.03 | 0.61–1.70 | 0.144     | 0.074  | 1.08 | 0.78–1.50 | 0.655     |
| Biochemical parameters           |                                  |              |    |          |           |                       |
| ALT (U/L)                        |                                  | 0.027        | 1.03 | 0.99–1.07 | 0.119     | 0.014  | 1.01 | 0.97–1.07 | 0.561     |
| AST (U/L)                        |                                  | 0.030        | 1.03 | 0.99–1.08 | 0.180     | 0.005  | 1.00 | 0.98–1.03 | 0.670     |
| BUN (mmol/L)                     |                                  | −0.252       | 0.78 | 0.61–0.99 | 0.044*    | −0.330 | 0.72 | 0.55–0.93 | 0.012*    |
| CREA (umol/L)                    |                                  | −0.021       | 0.98 | 0.95–1.00 | 0.096     | 0.003  | 1.00 | 0.98–1.03 | 0.823     |
| TBIL (umol/L)                    |                                  | 0.043        | 1.04 | 0.91–1.19 | 0.531     | 0.026  | 1.03 | 0.97–1.09 | 0.345     |
| DBIL (umol/L)                    |                                  | 0.161        | 1.17 | 0.79–1.75 | 0.427     | 0.137  | 1.15 | 0.97–1.37 | 0.117     |
| IBIL (umol/L)                    |                                  | 0.051        | 1.05 | 0.87–1.28 | 0.605     | 0.017  | 1.02 | 0.96–1.09 | 0.599     |

SpO2 blood oxygen saturation, HR heart rate at resting, SBP systolic blood pressure, DBP diastolic blood pressure, RBC red blood cell count, Hgb hemoglobin, Hct hematocrit, MCV mean corpuscular volume, MCH mean corpuscular hemoglobin, PLT platelets count, MPV mean platelet volume, WBC white blood cell, LYM% lymphocyte rate, LYM# lymphocyte count, ALT alanine aminotransferase, AST aspartate aminotransferase, BUN blood urea nitrogen, CREA creatinine, TBIL total serum bilirubin, DBIL direct serum bilirubin, IBIL indirect serum bilirubin

*p value indicates p < 0.05; **p value indicates p < 0.01
rate (eGFR). Previous study has suggested that a linear decrease of eGFR with the increase of altitude, which may related to a reduction of renal plasma flow (secondary to the increased sympathetic activity) [18]. In addition, our study found that there was only little change of BUN from sea level to 3700 m, which is inconsistent with previous study [22]. Because both BUN and creatinine were commonly used as renal function markers, we draw a scatter plot to explore the change of the relationship between BUN and creatinine at 50 m and 3700 m (See fig. 2). This figure showed that there is a strong linear correlation between BUN and creatinine at sea level but no significant correlation after ascent to 3700 m. The BUN level represent the urea concentration of plasma, which can be reabsorbed in inner medullary collecting duct (IMCD), while creatinine can not be reabsorbed [23, 24]. Some studies indicated that urea generation in hepatocytes can be obstructed by insufficient adenosine triphosphate (ATP) supply and depressed levels of arginine and citrulline after exposure to hypoxia, but the genesis of creatinine is relatively constant [25]. This may be an explanation to the change of relationship between BUN and creatinine after rapid ascending to high altitude.

The physiological risk factors for HAH at 3700 m
The elevation of altitude results in a lower partial pressure of oxygen in the inspired air, and SpO₂ is a direct parameter that reflect the oxygen delivery. Insufficient oxygen consumption of cerebral tissue leads to function disorder and cytotoxic oedema, which is the main cause of HAH [26]. In addition, increased HR reflect the activity of sympathetic nervous system, which can lead to higher cardiac output and vasoconstriction of viscera, promote the redistribution of blood (mostly into vital organs such as brain). The accumulation of fluid in the brain result in increased intracranial pressure (ICP), which is another crucial cause of HAH [6]. Multiple lines of studies have reported that reduced SpO₂ and increased HR are independent risk factors for HAH, which is supported by our findings [1, 7, 11].

Blood urea nitrogen is an independent risk factor for HAH at both sea level and 3700 m
Our results first found that BUN is an independent risk factor of HAH at both sea level and 3700 m, and the values of BUN at 3700 m positively associated with HAH severity. Although more evidence of this finding is lacking, there still can be some potential explanations.

The first possible explanation is that the urea concentration may reflect the oxygen supply and utilization in cells. As discussed above, the correlation between BUN and creatinine showed a good linearity at sea level but no correlation at 3700 m, suggest that the production of

**Table 5** Forward stepwise multivariate logistic regression for HAH at sea level and 3700 m (N= 318)

| Measurements at sea level (after variable selection) | β-coefficient | OR  | 95% CI   | p-value |
|------------------------------------------------------|--------------|-----|----------|---------|
| age                                                  | 0.075        | 1.08| 0.99–1.18| 0.092   |
| BUN                                                  | -0.259       | 0.77| 0.60–0.99| 0.040   |

| Measurements at 3700 m (after variable selection) | β-coefficient | OR  | 95% CI   | p-value   |
|--------------------------------------------------|--------------|-----|----------|-----------|
| age                                              | 0.090        | 1.09| 0.98–1.23| 0.110     |
| SpO₂                                             | -0.191       | 0.84| 0.76–0.93| 0.001**   |
| HR                                               | 0.029        | 1.03| 1.00–1.07| 0.042**   |
| SBP                                              | -0.019       | 0.98| 0.95–1.01| 0.091     |
| BUN                                              | -0.452       | 0.64| 0.46–0.88| 0.007**   |

SpO₂: blood oxygen saturation, HR: heart rate at resting, SBP: systolic blood pressure, BUN: blood urea nitrogen.

*p value indicates *p* < 0.05; **p value indicates *p* < 0.01.
BUN may be affected by high altitude environment, and the concentration of BUN may partially reflect metabolism status and the oxygen utilization status of hepatocyte. Relative to BUN, other liver function parameters such as ALT, AST and bilirubin were aimed at substantial damage of liver and biliary tract. Some vitro experiments demonstrated that under hypobaric hypoxia, ATP was decreased in multiple cell lines, and as the oxygen concentration was decreased, production of both urea in isolated rat hepatocytes declined [25, 27, 28]. Study on the effect of acute hypoxic hypoxia on the profile of plasma amino acids in rats showed that after exposure to hypoxia for 5 h, the concentrations of arginine and citrulline (which are related to the urea cycle) were depressed [25]. These findings implicate that the BUN concentration in plasma may reflect the oxygen-driven catabolism, and higher BUN may indicate better oxygen supply and utilization of hepatocytes, even brain cells, which is the main cause of HAH.

The second potential explanation is that the hyperosmolar properties of urea may help with reducing intracranial pressure and brain volume [29]. Through brain imaging of patients with acute mountain sickness, some studies showed that intracranial and extracellular water accumulation influenced by increased permeability of the blood–brain barrier, resulted in cerebral swelling, sulci disappearing and changing of grey matter [6]. These verified that the inflation of brain volume and elevation of ICP is a vital sign of HAH. In 1960s, urea became the first widely used hyperosmolar compound in clinic for reducing ICP and alleviating cerebral swelling. Because urea undergoes renal excretion, the dehydrating effect of exogenous urea can maintain certain osmotic pressure inside and outside the brain cell and prevent excessive accumulation of liquids and cerebral swelling. Because urea

Another possible explanation is the products from urea cycle, nitric oxide (NO). Arginine generated as intermediate products by argininosuccinate lyase during urea cycle, and is the basic substrate of nitric oxide synthase (NOS) for generating nitric oxide. Nitric oxide has a short half-life and rapidly diffuses into the vascular smooth muscle where it affects modulation of calcium ions, mediated by cyclic guanosine monophosphate (cGMP), leading to vasodilatation [33]. They have significant effects in relieving pulmonary hypertension, improve cardiac output and blood gas exchange [34]. However, relevant studies about the correlation between ICP, pulmonary hypertension and endogenic urea are still lacking.

Limitations
Limited by field study, the time of onset of headache of participants were recorded by memories, not precisely, which should be improved in future. After the onset of headache, participants have not descent to low altitude immediately, which not strictly satisfied the criteria of the International Classification of Headache Disorders. The sample size was small, and there are many other potential risk factors that can be considered in the study, such as nitric oxide and PaCO₂. The participants in our study were all young male individuals, which may limit extrapolation of our results.

Conclusions
Our study found the frequency of HAH was high (74.84%) after acute exposure to 3700 m. We confirmed that SpO₂ and HR at 3700 m are independent risk factors for HAH, and firstly identified the independent association between BUN and HAH at both sea level and 3700 m, which suggested that lower BUN may be a new independent risk factor for HAH.

Additional files

Additional file 1: The distribution and QQ-norm plot of SpO₂ at 50 m and 3700 m. (DOCX 168 kb)

Additional file 2: The incidence of mild, moderate and severe headaches after ascent to 3700 m altitude. (DOCX 16 kb)

Additional file 3: The Shapiro-Wilk normality test of parameters at 50 m and 3700 m. (DOCX 12 kb)

Abbreviations
ALT: alanine aminotransferase; AMS: acute mountain sickness; AST: aspartate aminotransferase; ATP: adenosine triphosphate; BMI: body mass index; BUN: blood urea nitrogen; cGMP: cyclic guanosine monophosphate; CREA: creatinine; CRFs: Structured case report forms; DBIL: direct serum bilirubin; DBP: diastolic blood pressure; eGFR: estimated glomerular filtration rate; HAH: high-altitude headache; Hct: hematocrit; Hgb: hemoglobin; HR: heart rate; IBIL: indirect serum bilirubin; ICP: intracranial pressure; IMCD: inner medullary collecting duct; IQR: interquartile range; LYM: absolute lymphocyte count; LYMP%: lymphocyte percentage; MCH: mean corpuscular hemoglobin; MCV: mean corpuscular volume; MPV: mean platelet volume; NO: nitric oxide; NOS: nitric oxide synthase; OR: Odds ratio; PLT: platelet count; RBC: red blood cell count; SBP: systolic blood pressure; SD: standard deviations; SpO₂: blood oxygen saturation; TBIL: total serum bilirubin; WBC: white blood cell count

Acknowledgements
The authors thank Wenyuan Duan, MD, Tongjian Wang, MD and Kai Dong, MM (Institute of Cardiovascular Disease, General Hospital of Jinan Military Region, China) for invaluable support during data collection. The authors also thank Yajun Yang, PhD, Dr. Xingdong Chen (Fudan University, China) and Ziyu Yan, Juan Zhang and Jiangli Xue (Fudan-Taizhou Institute of Health Sciences, China) for support with the data entry of this study. No one received compensation for his/her contribution.
Availability of data and materials

Unfortunately, we cannot provide raw data and materials. As stated in the informed consent signed with all participants, we would keep all personal information and subject materials confidential, which would only been used for research purpose, published as research results or conclusions. In addition, according to the cooperation agreement, the data and materials owned by our collaborators, we only have the authority to analyze and disclose the results.

Funding

This work was supported by the National Natural Science Foundation of China (31330038, 31521003, 31462026), Shanghai Municipal Science and Technology Major Project (2017SHZDZX01), Ministry of Science and Technology (2015FY1117000), Science and Technology Committee of Shanghai Municipality (16JC1400500), the 111 Project (B13016).

Authors’ contributions

LJ were responsible for study supervision and contributed to the study concept and design, data collection, data analysis, drafting and revision of the manuscript. KW contributed to study supervision, and were responsible for data collection, data analysis, drafting and revision of the manuscript. XM, YM and YL contributed to study supervision and data collection. WP contributed to the revise of the manuscript. MZ, YW, YL and XL contributed for data collection, data analysis, drafting and revision of the manuscript. XW, LJ were responsible for study supervision and contributed to the study design, data collection, data analysis, drafting and revision of the manuscript. LK contributed to the data collection. All authors read and approved the final manuscript.

Ethics approval and consent to participate

This study was approved by the Human Ethics Committee of Fudan University, Ethics approval and consent to participate contributed to the revise of the manuscript. MZ, YW, YL and XL contributed for data collection, data analysis, drafting and revision of the manuscript. XW, LJ were responsible for study supervision and contributed to the study design, data collection, data analysis, drafting and revision of the manuscript. LK contributed to the data collection. All authors read and approved the final manuscript.

Conflict of interest

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

1State Key Laboratory of Genetic Engineering, Collaborative Innovation Center for Genetics and Development, School of Life Sciences, Fudan University, Shanghai 200438, China. 2Ministry of Education Key Laboratory of Contemporary Anthropology, Department of Anthropology and Human Genetics, School of Life Sciences, Fudan University, Shanghai 200438, China. 3Human Phenome Institute, Fudan University, Shanghai 201203, China. 4Institute of Cardiovascular Disease, General Hospital of Jinan Military Region, Jinan 250022, Shandong, China. 5Key Laboratory of High Altitude Environment and Genes Related to Diseases of Tibet Autonomous Region, School of Medicine, Xizang Minzu University, Xianyang 712082, China. 6Six Industrial Research Institute, Fudan University, Shanghai 200433, China.

Received: 18 February 2018 Accepted: 2 July 2018

References

1. Buntscher M, Mairer K, Wille M, Broessner G (2011) Risk factors for high-altitude headache in mountaineers. Cephalalgia 31(6):706–711
2. Carod-Artal FJ (2014) High-altitude headache and acute mountain sickness. Neurology 299(5):533–540
3. Roach RC, Bartsch P, Hackett P, Oeltz O The Lake Louise acute mountain sickness scoring system: the Lake Louise AMS scoring consensus committee; 1999.
4. Headache Classification Subcommittee of the International Headache S (2004) The international classification of headache disorders: 2nd edition. Cephalalgia 24(Suppl) 1:9–160
5. Bees A, Kunkel R, Lance Jw, Nappi G, Pfaffenharr V, Rose FC, Schoneberg BS, Soyka D, TerHt-Hansen P, Welch KMA et al (2013) The international classification of headache disorders, 3rd edition (beta version). Cephalalgia 33(9):629–808
6. Wilson MH, Newman S, Imray CH (2009) The cerebral effects of ascent to high altitudes. Lancet Neurol 8(2):173–191
7. Bian SZ, Zhang JH, Gao XB, Li M, Yu J, Liu X, Dong JQ, Chen GZ, Huang L (2013) Risk factors for high-altitude headache upon acute high-altitude exposure at 3700 m in young Chinese men: a cohort study. J Headache Pain 14:35
8. Bian SZ, Jin J, Li QN, Yu J, Tang CF, Rao RS, Yu SY, Zhao XH, Qin J, Huang L (2015) Hemodynamic characteristics of high-altitude headache following acute high altitude exposure at 3700 m in young Chinese men. J Headache Pain 16:527
9. Harris NS, Wenzel RP, Thomas SH (2003) High altitude headache: efficacy of acetaminophen vs. ibuprofen in a randomized, controlled trial. J Emerg Med 24(4):383–387
10. Mampresò E, Maggiòni F, Varo F, Dicco C, Zanchin G (2009) Efficacy of oxygen inhalation in sumatrapitan reffactory “high altitude” cluster headache attacks. J Headache Pain 10(6):465–467
11. Lawley JS (2011) Identifying the possible risk factors for high-altitude headache in mountaineers. Cephalalgia 31(6):1677–1678
12. Sutherland AJ, Morris DS, Owen GC, Bron AJ, Roach RC (2008) Optic nerve sheath diameter, intracranial pressure and acute mountain sickness on Mount Everest: a longitudinal cohort study. Br J Sports Med 42(3):183–188
13. Guo WJ, Bian SZ, Zhang JH, Li QN, Yu J, Chen JF, Tang CF, Rao RS, Yu SY, Jin J et al (2017) Physiological and psychological factors associated with onset of high-altitude headache in Chinese men upon acute high-altitude exposure at 3700 m. Cephalalgia 37(5):336–347
14. Huang H, Liu B, Wu G, Xu G, Sun BD, Gao YG (2017) Hematological risk factors for high-altitude headache in Chinese men following acute exposure at 3,700 m. Front Physiol 8:801
15. Jones RM, Terhaard C, Zullo J, Tenney SM (1981) Mechanism of reduced water intake in rats at high altitude. Am J Phys 240(3):R187–R191
16. Westerterp KR, Meijer EP, Rubbens M, Robach P, Riahiel JP (2000) Operation Everest III energy and water balance. Pflügers Archiv : European J Physiol 439(4):483–488
17. Bestle MH, Olsen NV, Poulsen TD, Roach R, Fogh-Andersen N, Be P (2002) Prolonged hypobaric hypoxemia attenuates vasopressin secretion and renal response to osmostimulation in men. J Appl Physiol 92(5):1911–1922
18. Pichler J, Rischi L, Hefti U, Menz TM, Turk AJ, Bie P, Barthelmes D, Schoch OD et al (2008) Glomerular filtration rate estimates decrease during high altitude expedition but increase with Lake Louise acute mountain sickness scores. Acta Physiol 192(3):443–450
19. Hackett P, Rennie D (2002) High-altitude pulmonary edema. JAMA 287(17): 2275–2278
20. Naeije R (2010) Physiological adaptation of the cardiovascular system to high altitude. Prog Cardiovasc Dis 52(6):456–466
21. Goldfrash-Burnyanzov AS, Alper SL (2014) Short-term responses of the kidney to high altitude in mountain climbers. Nephril Dial Transplant 29(3):497–506
22. Shah MB, Braude D, Crandall CS, Kwack H, Rabinowitz L, Cumbo TA, Basnyat B, Bhuyan S, Nelson TM, Bhasyal G (2006) Changes in metabolic and hematologic laboratory values with ascent to altitude and the development of acute mountain sickness in Nepalese pilgrims. Wilderness Environ Med 17(3):171–177
23. Muller F, Dommergues M, Bussieres L, Lortat-Jacob S, Loirat C, Bartsch P, Knauth M (2007) Magnetic resonance imaging evidence of acute mountain sickness in mountaineers. Cephalalgia 27(15–16):1738–1745
24. Potts D, Ninez J, Renard P, Aegerter P, Dumez Y (1996) Development of human renal function: reference intervals for 10 biochemical markers in fetal urine. Clin Chem 42(11):1885–1886
25. Arguello E, Akuzawa M (1997) Renal clearance of endogenous creatinine, urea, sodium, and potassium in normal cats and cats with chronic renal failure. J Vet Med Sci 59(7):509–512
26. Kashiwagi T, Wilson DF, Erecinska M (1984) Oxygen dependence of cellular metabolism: the effect of O2 tension on gluconeogenesis and urea synthesis in isolated rat hepatocytes. J Cell Physiol 120(1):13–18
27. Kallenberg K, Bailey JM, Christ S, Mohr A, Roukenis R, Menold E, Steiner T, Bartsch P, Knauth M (2007) Magnetic resonance imaging evidence of cytotoxic cerebral edema in acute mountain sickness. J Cereb Blood Flow Metab 27(5):1064–1071
28. Lipton R, Whittingham TS (1982) Reduced ATP concentration as a basis for synaptic transmission failure during hypoxia in the in vitro Guinea-pig hippocampus. J Physiol 325:51–65
29. Heerken K, Schulze A, Hotz L, Bartsch P, Mairbaur H (2005) Hypoxia decreases cellular ATP demand and inhibits mitochondrial respiration of s549 cells. Am J Respir Cell Mol Biol 32(1):44–51
29. Otvos B, Kshettry VR, Benzel EC (2014) The history of urea as a hyperosmolar agent to decrease brain swelling. Neurosurg Focus 36(4)
30. Stubbs J, Pennybacker J (1960) Reduction of intracranial pressure with hypertonic urea. Lancet 1(7134):1094–1097
31. Matson DD (1965) Treatment of cerebral swelling. N Engl J Med 272:626–628
32. Go KG, van Woudeberg F, Wildring AG, Ebelis EJ, Beks JW, Smeets EH (1969) The penetration of 14C-urea and 3H-water into the rat brain with cold-induced cerebral oedema. Histological and autoradiographic study of the oedema. The effect of urovert. Acta Neurochir 21(2):97–122
33. Martinez-Romero R, Canelo A, Siles E, Oliver FJ, Martinez-Lara E (2012) Nitric oxide modulates hypoxia-inducible factor-1 and poly(ADP-ribose) polymerase-1 cross talk in response to hypobaric hypoxia. J Appl Physiol 112(5):816–823
34. Pearson DL, Dawling S, Walsh WF, Haines JL, Christman BW, Bazyk A, Scott N, Summar ML (2001) Neonatal pulmonary hypertension–urea-cycle intermediates, nitric oxide production, and carbamoyl-phosphate synthetase function. N Engl J Med 344(24):1832–1838

Ready to submit your research? Choose BMC and benefit from:
- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.
Learn more biomedcentral.com/submissions